ホーム>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>TM5441

TM5441

カタログ番号GC18173

TM5441 は、経口で生物学的に利用可能なプラスミノーゲン アクチベーター インヒビター 1 (PAI-1) の阻害剤であり、13.9 ~ 51.1 μM の IC50 値を持ち、いくつかのヒトがん細胞株で固有のアポトーシスを誘導します。 TM5441 は、Nω-ニトロ-1-アルギニン メチル エステル誘発心高血圧症と血管老化を軽減します。

Products are for research use only. Not for human use. We do not sell to patients.

TM5441 化学構造

Cas No.: 1190221-43-2

サイズ 価格 在庫数 個数
1mg
$41.00
在庫あり
5mg
$89.00
在庫あり
10mg
$135.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products
TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor 1 (PAI-1), a serine-protease inhibitor involved in thrombosis. It decreases survival of HT1080, HCT116, Daoy, MDA-MB-231, and Jurkat cancer cells with IC50 values ranging from 13.9 to 51.1 uM. TM5441 inhibits branching of human umbilical vein endothelial cells (HUVECs) in a vasculature assay in vitro when used at a concentration of 50 uM but does not affect HUVEC survival or apoptosis. It also disrupts tumor vasculature in HT1080 and HCT116 mouse xenograft models when used at a dose of 20 mg/kg per day. TM5441 prevents hypertension and cardiac hypertrophy and reduces periaortic fibrosis induced by L-NAME . It protects against high-fat diet-induced non-alcoholic fatty liver disease (NAFLD) in mice when administered concurrently with a high-fat diet or after glucose tolerance has developed. TM5441 also increases median lifespan by 4-fold and reduces signs of senescence in Klotho-deficient mice, a mouse model of aging.

レビュー

Review for TM5441

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TM5441

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.